chiara cremolini
chiara cremolini
Full Professor, University of Pisa
Verified email at
Cited by
Cited by
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
Primary tumor location as a prognostic factor in metastatic colorectal cancer
F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ...
Journal of the National Cancer Institute 107 (3), dju427, 2015
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin Oncol 27 (16), 2622-2629, 2009
Quantitative evidence for early metastatic seeding in colorectal cancer
Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ...
Nature genetics 51 (7), 1113-1122, 2019
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ...
The lancet oncology 11 (9), 845-852, 2010
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European journal of cancer 50 (1), 57-63, 2014
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ...
Journal of the National Cancer Institute 103 (1), 21-30, 2011
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
M Lambertini, A Toss, A Passaro, C Criscitiello, C Cremolini, C Cardone, ...
ESMO open 5 (2), e000759, 2020
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ...
Annals of Oncology 26 (4), 724-730, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer
C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, ...
Journal of Clinical Oncology 38 (28), 3314-3324, 2020
First-line chemotherapy for mCRC—a review and evidence-based algorithm
C Cremolini, M Schirripa, C Antoniotti, R Moretto, L Salvatore, G Masi, ...
Nature reviews Clinical oncology 12 (10), 607-619, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
The system can't perform the operation now. Try again later.
Articles 1–20